{"id":802389,"date":"2025-01-21T05:48:04","date_gmt":"2025-01-21T10:48:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/"},"modified":"2025-01-21T05:48:04","modified_gmt":"2025-01-21T10:48:04","slug":"shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/","title":{"rendered":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>\n <\/p>\n

, <\/p>\n

Jan. 21, 2025<\/span><\/p>\n

\/PRNewswire\/ — Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc.<\/b> (“Revance” or the “Company”) (NASDAQ: RVNC) of a class action securities lawsuit.<\/p>\n

\n

\n
\n \"Levi
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged<\/span> securities fraud<\/span> between February 29, 2024<\/span> and December 6, 2024<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/revance-therapeutics-inc-lawsuit-submission-form?prid=123844&wire=4<\/a>\u00a0<\/p>\n

\n RVNC<\/b>\u00a0investors may also contact Joseph E. Levi, Esq.<\/span> via email at\u00a0jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/b>The filed complaint alleges<\/span> that defendants made false statements and\/or concealed that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance “the exclusive right to import, market, promote, sell and distribute Teoxane’s line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and\/or amended; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n

\n WHAT’S NEXT? <\/b>If you suffered a loss in Revance during the relevant time frame, you have until March 4, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/b><\/p>\n

\n WHY LEVI & KORSINSKY: <\/b>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States<\/span>.<\/p>\n

\u00a0<\/p>\n

\n CONTACT:<\/b>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.<\/span>
Ed Korsinsky, Esq.<\/span>
33 Whitehall Street, 17th Floor
New York, NY<\/span> 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/shareholders-of-revance-therapeutics-inc-should-contact-levi–korsinsky-before-march-4-2025-to-discuss-your-rights–rvnc-302355530.html<\/a><\/p>\n

SOURCE Levi & Korsinsky, LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Jan. 21, 2025 \/PRNewswire\/ — Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/revance-therapeutics-inc-lawsuit-submission-form?prid=123844&wire=4\u00a0 RVNC\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) Revance was in material breach of the Distribution Agreement with … <\/p>\n

Continue reading “Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802389","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nShareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Jan. 21, 2025 \/PRNewswire\/ — Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/revance-therapeutics-inc-lawsuit-submission-form?prid=123844&wire=4\u00a0 RVNC\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) Revance was in material breach of the Distribution Agreement with … Continue reading "Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T10:48:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC\",\"datePublished\":\"2025-01-21T10:48:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/\",\"name\":\"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-01-21T10:48:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk","og_description":"PR Newswire NEW YORK , Jan. 21, 2025 \/PRNewswire\/ — Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/revance-therapeutics-inc-lawsuit-submission-form?prid=123844&wire=4\u00a0 RVNC\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) Revance was in material breach of the Distribution Agreement with … Continue reading \"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-21T10:48:04+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC","datePublished":"2025-01-21T10:48:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/","name":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-01-21T10:48:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-revance-therapeutics-inc-should-contact-levi-korsinsky-before-march-4-2025-to-discuss-your-rights-rvnc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights – RVNC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802389"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802389\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}